Arthritis is one of the world’s most common health problems. Aging and post-traumatic arthritis caused by injuries are commonly cited causes of the condition. Billions of patients suffer from debilitating arthritis pain in their backs, knees, and hands. Florida-based research company Cytonics has developed a method for injecting Alpha-2-macroglobulin, or A2M, to stop the progression of arthritis. The process works to inhibit disease progression and regenerate damaged cartilage in affected joints.
A2M, a natural inhibitor produced by the liver, protects cartilage from proteins known to cause osteoarthritis. Instead of being concentrated in joints to prevent arthritis, A2M molecules are disbursed throughout the body. As a solution to the problem, Cytonics developed a regenerative A2M concentrate for treatment. The medicine is injected directly into affected joints, delivering the A2M supplement to inhibit the progression of arthritis.
How Does A2M Work to Stop Arthritis?
When a patient is suffering from arthritis, chemicals that destroy cartilage affect his or her joints. Catabolic proteases, the chemicals cause cartilage to break down, result in pain and inflammation. The disease will eventually cause the cartilage to disappear completely, resulting in painful friction of bones rubbing together. In healthy joints, cartilage works as a buffer to prevent bone-on-bone contact.
A2M halts the progression of osteoarthritis at the molecular level by inactivating the chemicals that cause joint breakdown. As the A2M captures and neutralizes the damaging chemicals, the body will work to eliminate them. The joint will then begin to recover, as the inflammation is subdued, and harmful chemicals are no longer present. A2M remaining in the joint will promote tissue growth and the joint can begin the restoration process. The repaired damage will then lead to a pain-free joint.
Will A2M Work for Me?
A2M will improve the pain and damage of arthritis in most patients. The joint restoration process will work best when used early in arthritis treatment, before destruction has progressed. This will allow for the maximum amount of cartilage to be protected before becoming severely damaged. In those with untreated arthritis, A2M injections can still be effective. The restoration process may not be as thorough but will still inhibit disease progression.
The A2M injection can eliminate all pain associated with osteoarthritis. Our patients have found relief for spinal, knee, and soft tissue pain. The regenerative process will work to rebuild healthy joints, allowing patients to return to active lifestyles.
Back pain is one of the most common conditions that lead Americans to seek help from their doctor. Often, it’s difficult to pinpoint the cause and even harder to treat. For those with chronic back pain, there’s new hope.
A2M injections use a naturally-occurring molecule to reduce inflammation and help alleviate pain in injured areas.
Back Pain Statistics
The numbers are staggering. A Statista 2017 survey found 54 percent of Americans reported suffering from neck and back pain for five years or longer. The American Physical Therapy Association says 37 percent of those with back pain don’t seek help. Those who suffer say back pain impacts their ability to participate in daily living, stay physically active, or get a healthy amount of sleep.
Women are more likely to suffer from back pain than men, but both genders say their condition hinders their ability to do their job. People report taking medication, seeing a physical therapist, or trying doctor-recommended treatment for their pain with varying levels of success.
Americans and insurance companies spend $50 billion dollars a year on back pain treatment. The estimated cost of lost wages, reduced productivity and legal overhead is over $100 billion a year.
Problems with Treatment and Diagnosis
The back, spine, and joints are all components of a complex system with many moving parts. Pain is subjective, and what patients are experiencing is often hard for them to describe. Even when doctors are relatively certain of the cause, no one treatment works for everyone, so treatment can feel like a process of trial and error. Sufferers become frustrated and feel like pain must be something they just have to live with.
Fortunately though, Alpha-2-Macroglobulin (A2M) injection treatment is one way many sufferers have found relief from back pain.
How A2M Works
A2M is a molecule that the human body makes on its own, but it’s normally too large to fit in the tight spaces between joints and discs. Injections place A2M where pain originates. The molecule binds to destructive enzymes to prevent tissue breakdown and reduce inflammation. A2M sticks around for a long period of time, sopping up enzymes that lead to joint degradation and cartilage loss and through natural processes, used up A2M is flushed out of our system.
A2M therapy jump-starts natural healing processes and encourages the growth of healthy tissue. It prevents cartilage breakdown within the affected joint.
The molecule is gathered from the patient’s own blood and later injected in a super concentrated dose. After the injection, patients typically feel restored mobility the very same day. Relief often lasts for months when combined with follow-up therapy. Cytonics is the ONLY company dedicated to the research and development of A2M, and has optimized processes maximizing the ability of A2M to protect cartilage.
In the U.S., over 30 million people are treated for back pain yearly, and osteoarthritis (OA) related joint pain affects nearly 27 million. In all, musculoskeletal disease burdens our nation with substantial human suffering, lost productivity, missed work, and excessive medical expenses. Our mission at Cytonics is to develop novel diagnostic and therapeutic products for OA, back, and joint pain.
Become a Cytonics Investor
We’re excited to share that Cytonics is gearing up to offer company shares to not only accredited investors, but also anybody interested in investing in a growing and proven medical technology company. We are currently working with auditors and regulators to setup a crowdfunding platform so that investors of all sizes can take advantage of this financial opportunity.
How do Investors make money with Crowdfunding?
There are different ways investors can make money through crowdfunding investments. Investors can own a share or dividend, which represents them owning a part of the business. Potentially, investors can also make money if a company is sold/acquired, goes public with an IPO, or through a secondary market trade if the shareowner decides to sell his or her dividend. Like any investment, there are risks involved and there is no financial guarantee, so it’s important to invest in solid, proven companies.
What should Cytonic investors know?
Cytonics first discovered a unique “bio-marker” that assists physicians in diagnosing pain and improving outcomes by pinpointing the source of pain. This led to identification of a unique protein, Alpha-2 Macroglobulin (A2M), made by the body that stops pain AND also protects cartilage. We have developed a range of therapeutic products based on A2M.
We intend to market our products to the more than 50,000 surgeons and physicians that treat patients for osteoarthritis and orthopedic related pain in the U.S. and around the world.
What are Cytonics’ products?
Research has shown that an inflammatory cascade of proteins causes back and joint pain. Our FACTÔ diagnostic assay measures the presence of a unique Fibronectin- Aggrecan Complex (FAC) in a fluid specimen taken from patients with spine or joint related pain. FACT is a Lab Developed Test (LDT) that is processed in Cytonics’ CLIA certified lab. Two versions have been launched in the US: FACT for Molecular Disc Analysis, and FACT for Joint Diagnostics.
Based on Cytonics’ in-depth knowledge of the pain cascade and discovery of FAC, we have also developed a treatment that inhibits cartilage degeneration and prevents the formation of FAC. Our APICÔ System utilizes a unique process to concentrate plasma proteins from a patient’s own blood. We have recently completed a successful Phase l/ll clinical trial with APIC- CF. Moreover, our recombinant platform has been shown to slow the progression of osteoarthritis in preclinical models by Cytonics and by independent researchers at Brown University (Arthritis Research & Therapy 2017 19:175). Additional new products are underway in development as well.
Does Cytonics’ have patents?
Cytonics has invested over $1.5M in patent development, and has filed numerous domestic and international patent applications on our diagnostic and therapeutic products. We have already received 7 patent approvals.
What capital has already been raised for Cytonics?
The company has received over $18M in funding, including a prestigious $1.8M grant from the National Institute of Health. An international orthopedic implant company purchased a minority interest in Cytonics in 2011 and made an additional investment in 2013. Furthermore, we closed a Series B round at $4.00/ share, with $2M raised in 2015.
Cytonics is currently pursuing opportunities for a C round of funding via a convertible debt offering or a regulation A+ tier 2 IPO to fund preclinical trials of its recombinant A2M.
How to get started as a Cytonics investor
To be added to our monthly newsletter and to receive future investment information about Cytonics, contact email@example.com. Additionally, follow us on Facebook and Twitter to learn more about our IPO, new products and research.
Alpha-2-macroglobulin, or A2M, is a cartilage catabolic factor inhibitor with the power to stop the progression of osteoarthritis (OA). It’s found naturally in the blood. Treatments using A2M through Cytonics Corporation may be able to help patients with OA by preventing the breakdown and loss of cartilage. Cytonics uses its own original, breakthrough technology to administer these treatments directly to the joint space in need. Here’s what you need to know about this innovative treatment.
How Does A2M Work to Stop Osteoarthritis?
Osteoarthritis is the most common form of arthritis, and one of the most prevalent health problems today. It affects about 27 million Americans. OA is a degenerative disease in which the tissues that cover joints break down and eventually wear away completely. This results in the two bones rubbing painfully together, instead of gliding, as they do when joints are healthy. Thanks to Cytonics’ A2M injection treatment, OA doesn’t have to be forever. Recent scientific studies indicate that Cytonics’ A2M injection treatment may offer lasting protection from joint collapse.
During our A2M injection treatments, we use the molecular technology we developed to concentrate the A2M in your blood, in order to deliver high amounts to the joint space. A2M is a special inhibitor because it protects the cartilage in your body from the destructive proteins (catabolic proteases) that break down cartilage and cause OA. Treatments using A2M, such as Cytonics’ unique therapy, mimic natural processes to prevent cartilage loss, promote tissue growth, and support the restoration of a healthy joint.
A2M injections with Cytonics’ special molecular technology results in plenty of A2M available to bind and stop chemicals in joints that are responsible for causing OA. The A2M fills the joint space, captures the catabolic proteases, and neutralizes their harmful degenerative effects – effectively halting osteoarthritis and related pain in their tracks. A2M doesn’t stop there. It then works to promote the regrowth of lost or worn-away cartilage in the joint to repair damage and ultimately restore pain-free use of the joint.
A2M Injection Treatment Clinical Trials
Cytonics Corporation is the only company with patented technology for concentrating A2M. Our device uses the patient’s own blood to remove the cells and inject concentrated A2M to the affected joint.
Our special Autologous Protease Inhibitor Concentrate System has received Food and Drug Administration (FDA) approval to move onto the Investigational New Drug Clinical Trial stage for the treatment of osteoarthritis. The ongoing 2016 study indicates a strong safety profile and reduction of pain after eight weeks – a positive step for the future of alpha-2-macroglobulin injection treatments.
It’s common to experience some soreness or stiffness in joints or in the back, especially after waking up or after sitting for an extended period. If this is happening more frequently, you may be wondering if these are the early signs of osteoarthritis (OA). If so, you are not alone. The most common cause of joint disorder in the US is osteoarthritis, affecting 10 percent of men and 13 percent of women over 60. This number is poised to grow over the coming years.
Here are some signs to look for that may indicate osteoarthritis.
Pain and Tenderness
Early arthritis pain manifests as an aching pain and tenderness. Moving a joint in a particular way may cause a sharper pain that can indicate this is more than normal soreness. Additionally, you may experience a tenderness revealed by pressing on the joint. If this pain and tenderness continues or returns regularly, this may well be an early sign of osteoarthritis.
Stiffness of Joints
Taken alone, it can be hard to discern if the stiffness you feel on waking up or after sitting for a while is a symptom of osteoarthritis or a normal part of life. As the joints warm up, the stiffness is likely to be relieved, further obscuring the fact that this may well be a symptom of a bigger problem. If this stiffness is accompanied by one or more of the other symptoms listed here, it may well be an indicator of osteoarthritis.
Lost Range of Motion
Joints have a natural range of motion that allows freedom of movement. As osteoarthritis progresses, you may observe this range of motion becoming increasingly limited. Pay attention if your knee no longer bends as far as it used to, or if you are unable to raise your arm all the way anymore. This usually comes on gradually, but becomes more apparent as the osteoarthritis progresses.
Symptoms With No Apparent Cause
Waking up with a sore, stiff back may seem normal. If you find yourself sore and stiff during the day without being able to identify an activity that may have brought the soreness about, this may well be a sign that osteoarthritis is the cause.
If you observe these symptoms, it is best to consult your doctor about them sooner rather than later. Getting an early diagnosis can help you be proactive in taking measures to combat the progression of the disorder and prolong your quality of life.
Treatment for OA
An emerging treatment option for osteoarthritis includes Alpha-2-Macroglobulin (A2M) injections. A2M is a natural protein the body produces that prevents cartilage from breaking down, thus stopping the progression of OA and providing joint pain relief.
To find a physician in your area who offers A2M treatment, click here or contact Cytonics at firstname.lastname@example.org.
Understanding the roles of A2M, including inflammatory cytokines, can be useful in understanding your treatment options and how you can expect them to relieve your pain. What can at first appear to be an alphabet soup of unfamiliar terms will be clear as you understand the roles these chemicals play in your joint pain.
Our bodies are a wonder of chemical production and regulation. Over time, however, certain chemicals can get out of balance and produce painful effects. Your body produces cytokines that help the immune system in fighting diseases. However, when certain types of these cytokines are present in sufficient quantities in your joints, inflammation, pain, and destruction of cartilage can result. Many other factors, of course, can produce joint pain as well, but inflammation as a result of these bad chemicals is commonly a factor in producing joint pain.
A2M and Treating Inflammation
A2M is a natural protein produced by your body and present in blood plasma. A2M’s role is to protect tissue (like cartilage) from some of these “bad chemicals” (inhibiting cartilage breakdown for example). Joint pain is often associated with low levels of A2M. A study from Brown university showed that concentrated injections of A2M into the joint can effectively fight cartilage damage and inflammation. A2M destroys the chemicals causing inflammation and joint pain and returns the joint to proper balance. A2M is a relatively large molecule, and there can be several reasons, such as an injury, that may keep A2M from reaching joints effectively. By injecting this powerful protein directly into the joint, A2M can provide joint pain relief and protect cartilage by destroying the chemicals that harm the joint.
How A2M Does Its Job
Produced in the liver, the A2M protein circulates through a healthy blood stream carried in your plasma. When A2M comes across cartilage destroying enzymes, special sites on the protein bind with the enzymes to trap and then carry them away. Once the A2M protein has filled each of its binding sites, the protein is flushed from the body, thus removing the harmful chemicals that destroy your cartilage. When the system is healthy, this takes place naturally without any special intervention. After an injury, however, the system may not function properly, which results in joint pain. Even a minor injury can impede the flow of A2M, causing discomfort and limitation that can be misleading. Additionally, as we age, the process of A2M circulation tends to become less effective. In these cases, a concentrated injection of A2M may restore the joint to proper working order and relieve the inflammation and pain.
At Cytonics we’re dedicated to discovering and developing therapeutics based on the protease inhibitor A2M. Contact us to learn more about our research and treatments.